Executive summary of the Public Launch of the recommendations

On 4 February 2025 in Belgium, we proudly presented key highlights from the final recommendations from the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life endpoints – Innovative Medicines Initiative (SISAQOL-IMI) Consortium during a public launch.

This international and multi-stakeholder initiative marks a significant milestone in the field of oncology, aiming to enhance the evaluation of cancer treatments by systematically incorporating Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) endpoints into cancer clinical research.

More information about the key takeaways from the event including how different stakeholders will implement the recommendations can be found in our press release, available here.

We invite you to explore the executive summary about the public launch to understand the framework, recommendations, and the collaborative efforts that underpin the SISAQOL-IMI initiative. It is available here.